Aberdeen Group plc Raises Stock Holdings in Oculis Holding AG $OCS

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Aberdeen Group plc lifted its holdings in shares of Oculis Holding AG (NASDAQ:OCS - Free Report) by 24.1% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,253,119 shares of the company's stock after purchasing an additional 243,695 shares during the quarter. Aberdeen Group plc owned about 2.87% of Oculis worth $23,847,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of OCS. Kestra Private Wealth Services LLC purchased a new position in Oculis during the 1st quarter valued at about $234,000. Citadel Advisors LLC purchased a new position in Oculis during the 4th quarter valued at about $389,000. Bank of America Corp DE boosted its holdings in Oculis by 58.2% during the 4th quarter. Bank of America Corp DE now owns 28,980 shares of the company's stock valued at $493,000 after acquiring an additional 10,667 shares during the period. Bellevue Group AG purchased a new position in Oculis during the 4th quarter valued at about $170,000. Finally, XTX Topco Ltd purchased a new position in Oculis during the 4th quarter valued at about $225,000. 22.30% of the stock is currently owned by hedge funds and other institutional investors.

Oculis Stock Up 1.4%

OCS traded up $0.25 on Thursday, reaching $17.80. The company's stock had a trading volume of 2,529 shares, compared to its average volume of 44,659. The stock has a 50 day moving average of $18.45 and a two-hundred day moving average of $18.78. The company has a market capitalization of $777.18 million, a price-to-earnings ratio of -6.74 and a beta of 0.27. Oculis Holding AG has a fifty-two week low of $10.79 and a fifty-two week high of $23.08.

Wall Street Analysts Forecast Growth

Separately, Chardan Capital raised their target price on Oculis from $28.00 to $33.00 and gave the company a "buy" rating in a report on Friday, May 9th. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat, the stock has an average rating of "Buy" and a consensus price target of $35.33.

Oculis Profile

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.